📰 Curated from NPR
📖 Read full article→
A new flu vaccine geared to older people is coming soon - NPR
Technology and ScienceBy Rob Stein8/6/20261 min read
The first mRNA-based flu shot to be approved by the Food and Drug Administration will be ready for the upcoming flu season. Moderna, the vaccine's maker
✨ Key Highlights
- The U.S. Food and Drug Administration has approved Moderna's mRNA-based seasonal influenza vaccine, marking the first flu shot using mRNA technology to gain approval.
- The vaccine is expected to be available for the upcoming flu season, offering a new option for immunization.
- Moderna's shot is geared specifically toward older people, a population that tends to be more vulnerable to serious complications from influenza.
- The approval builds on mRNA technology, the same platform used in COVID-19 vaccines, extending its application to seasonal flu protection.
- The rollout represents a notable development in flu prevention efforts, potentially expanding the range of vaccines available to at-risk groups ahead of flu season.
For the latest stories on the science of healthy living, subscribe to NPR's Health newsletter.
The Food and Drug Administration approved Moderna's mRNA-based vaccine against seasonal influenza for